Back to Journals » Oncolytic Virotherapy » Volume 4

Oncolytic virotherapy for head and neck cancer: current research and future developments

Authors Malhotra A, Sendilnathan A, Old M, Wise-Draper T

Received 26 March 2015

Accepted for publication 12 May 2015

Published 20 July 2015 Volume 2015:4 Pages 83—93

DOI https://doi.org/10.2147/OV.S54503

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Faris Farassati


Akshiv Malhotra,1 Arun Sendilnathan,1 Matthew O Old,2 Trisha M Wise-Draper1

1
Division of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, 2Department of Otolaryngology-Head and Neck Surgery, Ohio State University, Columbus, OH, USA

Abstract: Head and neck cancer (HNC) is the sixth most common malignancy worldwide. Despite recent advancements in surgical, chemotherapy, and radiation treatments, HNC remains a highly morbid and fatal disease. Unlike many other cancers, local control rather than systemic control is important for HNC survival. Therefore, novel local therapy in addition to systemic therapy is urgently needed. Oncolytic virotherapy holds promise in this regard as viruses can be injected intratumorally as well as intravenously with excellent safety profiles. This review will discuss the recent advancements in oncolytic virotherapy, highlighting some of the most promising candidates and modifications to date.

Keywords: head and neck cancer, virotherapy, oncolytic viruses

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]